Nutriband FY27 Q2 net loss narrows 56% to $880,561; revenue falls 29.71% to $437,514 - NTRB News | RalliesNutriband FY27 Q2 net loss narrows 56% to $880,561; revenue falls 29.71% to $437,514
N
NTRB• Q2 results
- Nutriband posted a Q2 net loss of $880,561, narrowing 55.98% from $2 million a year earlier.
- Revenue fell 29.71% to $437,514, reflecting weaker Pocono Pharmaceuticals sales after a key customer shifted operations to Asia.
- Operating loss narrowed 55.55% to $890,637 as selling, general and administrative expense dropped 53.03% to $750,317.
- Research and development expense declined 42.73% to $322,194, primarily on lower labor costs tied to Aversa Fentanyl development.
Cash position
- Cash and cash equivalents totaled $3.42 million at July 31, 2026, down from $4.57 million at Jan. 31, 2026.
•
